Robert McBane leads a discussion on the latest techniques and considerations in AAA surveillance and open vs endovascular repair in elective and urgent settings.

Does population screening for BRCA mutations portend a eugenics future, as in 'Gattaca,' or a practical means to reduce the risk for breast and ovarian cancer? Dr. Kathy Miller weighs the issues.

UPDATED with Transcript // Focusing on the positive trials from ESC, including PARADIGM HF and ODYSSEY, Dr Fuster and panelists end on the sobering note of poor medication adherence.

Dr. David Johnson discusses a new paradigm for endoscopic colorectal cancer surveillance in patients with inflammatory bowel disease that spells the end for random biopsies.

Patients might not bring them up, but hemorrhoids and anal fissures, along with their consequences, are common complaints. Here's how to evaluate and treat them.

Dr. David Kerr thoughtfully responds to news that religious leaders support a proposed UK law for physician-assisted suicide and ponders whether he could offer his cancer patients this option.

Dr. Andrew Kaunitz reviews a paper describing a technique for contained power morcellation within a large plastic insufflated bag.

Dr. Mark Kris discusses the risks and benefits of using neoadjuvant therapy vs chemoradiation preoperatively for patients with stage IIIA lung cancer.

Dr. David Kerr reports on a study fueling the controversy about which CRC patients with unresectable liver mets who receive conversion chemotherapy are candidates for secondary resection or ablation.

NCI budget cuts to 2 clinical trial programs endanger patients and cripple research, says Dr. Bruce Cheson, who calls for the feds to loosen their stranglehold on clinical trials.